Pharming Overview
Download
1 / 9

Pharming Overview - PowerPoint PPT Presentation


  • 102 Views
  • Uploaded on

Pharming Overview. May 2006.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Pharming Overview' - miette


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Pharming Overview

May 2006

This presentation contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Powered by Bioscience, Focused on Products


Overview
Overview

  • Based in Leiden, Netherlands and USA

  • Euronext listing;1989 - 2001 ‘Research Era’

  • Production of recombinant proteins for restoration and repair

  • Role of protein cascades (Complement, Clotting)

  • 2002 - 2005 ‘Turnaround & Refocus’

  • 240 40 60 employees

  • Lead product rhC1INH being filed for HAE

  • Clinical work on major new indications

  • rhLactoferrin filed for GRAS indication in USA

  • rhFibrinogen and rhCollagen development

  • Novel protein manufacturing system validated

History

Technology

Organisation

Products


Strategic Evolution

Survival

Focus

Innovation

Collaboration

  • Financing

  • Research

  • Organisation

  • rhC1 INH

  • rh LF

  • Cash Flow

  • Restructuring

  • Compassionate Use

  • Manufacturing

  • Marketing

  • Diosynth

  • Paul Capital

  • Novathera

  • DNage

2001A 2002A 2004A 2005A 2006 - 07

Equity€ (1) M € 11 M € 36 M € 29 M € 50 M +

Debt € (24) M € (5) M Near Zero Near Zero Near Zero

Annual Loss€ (54) M € (1) M € (14) M € (18) M ZCB

Employees 250 40 48 60 60+

Products 1 1 4 4+ 6+

Mkt Cap€ 4 M € 16 M € 150 M € 325 M


Product Pipeline

Accelerate Product Flow to the Market

Status

Product

Application

Market Size

rhC1INH

rhFibrinogen

rhFib Sealant

rhLactoferrin

rhCollagen

Novathera Combos

Technology

> € 500 million

> € 1 billion

> € 1 billion

€ 100 million

> € 1 billion

> € 1 billion

> € 1 billion

> € 1 billion

Phase III

Filing in first market

In the clinic

Intermediate

Device

Food (GRAS)

Device

Intermediate

Device

Under

Development

Licensing

  • HAE

  • New Indications

  • Intermediate

  • Control bleeding

  • Nutraceutical

  • Anti-infective

  • Intermediate

  • Cosmetic / Other

  • Tissue Repair

  • Catheters, Stents

  • Protein Production


Protein production technology
Protein ProductionTechnology

Select

protein

Generate

genetic

constructs

Develop

founder/

mini-herd

Expand

herd

Purify

protein

from milk

Formulate

Protein

therapeutic


Hae patient centric approach
HAE - Patient Centric Approach

A congenital deficiency of functional C1 inhibitor (C1INH) characterised by recurrent

localised angioedema due to uncontrolled activation of complement and contact systems

22,000 patients, 160,000 attacks per year

relationship with patient organizations

facilitating

patient care

Patient

Register

share information with regulatory authorities

relationships with key opinion leaders


Rec human c1 inhibitor phase iii for hae
Rec. Human C1 inhibitor Phase III for HAE

  • Rapid relief

  • (usually 15 minutes)

  • Complete resolution

  • (12 - 24 hours)

  • No ADRs reported

  • Report published

  • April 2005


Rec human lactoferrin filed with us fda for gras
Rec. Human LactoferrinFiled with US FDA for GRAS

  • For functional and

  • sport foods

  • Doses of upto 2g/kg in

  • toxicity studies

  • Safe for oral use

  • Report published

  • Jan 2006


Future outlook 2006 08 capitalize on solid financial position
Future Outlook 2006 – 08Capitalize on solid financial position

  • Strong news flow from filings, partnerships and launches for rhC1INH and rhLF

  • Partnerships for Pharming technology platforms and product pipeline

  • Generate sustainable revenues via rhC1INH and rhLF launches

  • Establish critical mass to build a biotechnology company with world class R&D and commercial capabilities


ad